What is Mesoblast?
Founded in 2004 and headquartered in Melbourne, Victoria, Australia, Mesoblast is a prominent biopharmaceutical firm dedicated to the development and commercialization of allogeneic cellular medicines. The company's therapeutic pipeline spans critical areas including cardiovascular diseases, spine orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory conditions. Mesoblast's strategic focus on regenerative medicine positions it as a key player in addressing unmet medical needs through advanced cell-based therapies.
How much funding has Mesoblast raised?
Mesoblast has raised a total of $744.3M across 8 funding rounds:
Stock Offering
$68.3M
Share Placement
$40M
Debt
$75M
Share Placement
$51M
Share Placement
$90M
Corporate Investment
$110M
Share Placement
$260M
Stock/Share Issuance
$50M
Stock Issuance/Offering (2015): $68.3M with participation from Undisclosed
Share Placement (2017): $40M led by Undisclosed
Debt (2018): $75M supported by Hercules Capital
Share Placement (2019): $51M featuring Undisclosed
Share Placement (2020): $90M backed by Undisclosed
Corporate Investment (2021): $110M with participation from Surgcenter
Share Placement (2025): $260M, investors not publicly disclosed
Stock/Share Issuance (2025): $50M, investors not publicly disclosed
Key Investors in Mesoblast
Hercules Capital
Hercules Capital is a specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in technology, life sciences, and sustainable and renewable technology industries.
What's next for Mesoblast?
The recent major strategic investment in Mesoblast signals a critical phase for the company, likely aimed at scaling its operations, advancing clinical trials, and potentially preparing for commercial launch of its lead product candidates. This significant backing, part of its $744.3M in total capital raised, suggests strong investor confidence in Mesoblast's technology and market potential. The company is expected to leverage this financing to accelerate its R&D initiatives and expand its global reach, further solidifying its position in the regenerative medicine landscape.
See full Mesoblast company page
